Management of Severe Anxiety with Normal Laboratory Values
Your patient's normal AM cortisol (8.8 µg/dL) and free T3 (3.8 pg/mL) effectively rule out endocrine causes of her anxiety, so you should initiate cognitive behavioral therapy (CBT) as first-line treatment, with SSRIs or SNRIs as secondary options if psychotherapy alone is insufficient. 1
Interpretation of Laboratory Results
Your patient's laboratory values are reassuring:
- AM cortisol of 8.8 µg/dL is normal (reference range typically 5-25 µg/dL), excluding both Cushing's syndrome and adrenal insufficiency as contributors to her anxiety
- Free T3 of 3.8 pg/mL is normal, ruling out thyroid dysfunction as an anxiety trigger
The guidelines explicitly state that diagnosis of an anxiety disorder requires ruling out alternative causes such as thyroid disease or drug use 1. You've done this appropriately. The research showing associations between cortisol abnormalities and anxiety 2, 3, 4 is not applicable here since your patient has normal cortisol levels.
Treatment Algorithm
First-Line: Psychological Interventions
Start with CBT or other psychotherapy as the initial treatment 1. The 2020 Women's Preventive Services Initiative guidelines are explicit that "cognitive behavioral therapy (CBT) and other forms of psychotherapy are initial treatments for most patients, whereas medications are usually secondary" 1.
The evidence supporting psychological interventions is robust:
- 65.9% of anxiety interventions are effective in reducing symptoms 5
- 77.8% maintain gains at follow-up 5
- Mindfulness and relaxation interventions show the strongest effects (effect size g = 0.345-0.347) on stress biomarkers 6
Second-Line: Pharmacotherapy
If psychotherapy alone is insufficient or the patient prefers combined treatment, add SSRIs or SNRIs as secondary treatment 1. The guidelines specifically recommend these medication classes for anxiety disorders in women.
Research supports this approach: SSRIs reduce both anxiety symptoms and cortisol hyperactivity when present 2, though your patient's normal cortisol suggests her HPA axis is functioning appropriately.
Key Clinical Considerations
Screen for comorbid depression: The estimated prevalence of anxiety disorders in patients with major depressive disorder is 56% 1, and anxiety with comorbid depression significantly increases suicide risk 1. Use validated screening tools for depression alongside anxiety assessment.
Assess for substance use and PTSD: These commonly co-occur with anxiety disorders 1 and require specific management approaches.
Consider integrated primary care delivery: If available, embedded behavioral health providers in primary care settings improve access to psychological treatments that most patients prefer over medication 5.
Common Pitfalls to Avoid
- Don't jump to pharmacotherapy first simply because it's faster or more familiar—the evidence clearly prioritizes psychotherapy as initial treatment 1
- Don't order additional endocrine testing (like dexamethasone suppression tests or 24-hour urinary cortisol) when screening labs are normal—this leads to unnecessary costs and potential false positives
- Don't dismiss the severity because labs are normal—anxiety disorders greatly impair function in work, social settings, and personal relationships regardless of hormone levels 1